Valneva’s Brazil Vaccine Green Light Comes With a Stock-Market Catch
Brazil’s Anvisa has authorized Instituto Butantan to manufacture Valneva’s chikungunya vaccine locally, shifting production from France. The vaccine, branded Butantan-Chik, is cleared for adults 18–59 and may enter Brazil’s public health system. Valneva shares fell 7.6% in Paris ahead of its Q1 results. Chikungunya caused over 127,000 cases and 125 deaths in Brazil in 2025.